Navigation Links
Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
Date:6/27/2011

SAN DIEGO and ST. LOUIS, June 27, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, and Novus International Inc., a leading manufacturer of animal and human nutrition and health products, today announced a strategic collaboration to jointly develop and commercialize a suite of new enzyme products from Verenium's late-stage product pipeline in the animal nutrition and health area globally.

"We are extremely enthusiastic about our partnership with Novus, the potential opportunity it represents for the continued development of our pipeline and for Verenium to become a more active participant in the animal health and nutrition marketplace with our suite of high-performance enzyme products," said James Levine, President and Chief Executive Officer at Verenium. "Novus brings world-class leadership and experience launching products in this market, and with our combined skills, we look forward to working closely as partners to commercialize a series of market-leading products over the coming years."

Thad Simons, President and Chief Executive Officer of Novus International adds, "We are very excited about our partnership with Verenium, as it will propel Novus toward new solutions to performance challenges and help us as we work to add further value to our customers' businesses. Verenium's approach to product development is very innovative and based on the highest standards of science. This partnership is a natural alignment and we expect to deliver great results for our industry working together."

Key terms and highlights of the collaboration include:

  • The initial focus of the partnership will be on select late-stage product candidates from Verenium's pipeline targeting the poultry, swine, beef, dairy, aquaculture and companion animals
    '/>"/>

  • SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
    3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
    4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
    5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    6. Verenium Announces First Commercial Cellulosic Ethanol Project
    7. Verenium Announces Organizational Changes
    8. Verenium Completes Amendment to 8% Senior Convertible Notes
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Announces Reverse Stock Split to Take Effect September 9
    11. Verenium 1:12 Reverse Stock Split Takes Effect
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/26/2015)... Feb. 26, 2015  NuGene International, Inc. ("NuGene") ... for skin and hair rejuvenation, has announced that ... of record for investor relations and strategic communications. ... distribution, sales and diversification strategies – and we ... prospective shareholders," stated Ali Kharazmi CEO of NuGene ...
    (Date:2/26/2015)... IL (PRWEB) February 26, 2015 Already ... its gauging line by expanding its Length Gauge offerings ... ACANTO gauges. , Specifically, HEIDENHAIN’s pencil probe-style ... improved force specification. Two new 1Vpp, 12mm stroke ... lower force applications. One is a variant with a ...
    (Date:2/26/2015)... Fla. , Feb. 26, 2015  Dyadic ... company whose patented and proprietary technologies are used ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... report its financial results for year ending December ... 11, 2015 and will host a conference call ...
    (Date:2/26/2015)... 2015  Epic Sciences announced today that President and ... the 35th Annual Cowen and Company Health Care Conference ... Room, 3rd Floor. The conference will be held at ... Epic is developing diagnostic tests of high clinical ... changes that occur during the course of cancer treatments. ...
    Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2
    ... Schering-Plough Corporation (NYSE: SGP ) will provide ... P. Koestler, Ph.D., executive vice president and president, Schering-Plough ... Conference in San Francisco on Monday, Jan. 12, at ... is expected to talk about the company,s R&D pipeline ...
    ... LONDON, RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., ... that GSK has resubmitted the New Drug Application (NDA) ... approval of Solzira (TM) (gabapentin enacarbil) Extended ... Restless Legs Syndrome (RLS). The FDA had requested ...
    ... LONDON, January 9 UK medical technology company,BioCeramic ... Stephan Rietiker,has joined the company,s Board of Directors. ... in BioCeramic Therapeutics, targeted sectors,particularly as former President ... follows the recent appointment of another renowned,figure, Sir ...
    Cached Biology Technology:GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 3Dr Stephan Rietiker Joins BioCeramic Therapeutics 2
    (Date:1/22/2015)... WINSTON-SALEM, N.C. , Jan. 16, 2015  A man-made ... working memory and other mental capabilities in adults with ... a pilot study led by researchers at Wake Forest ... 60 adults diagnosed with amnesic mild cognitive impairment (MCI) ...
    (Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
    (Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
    Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
    ... low levels of an asbestos-like mineral from Montana more ... for lung disease today, according to research from the ... a mineral with a flaky, fluffy-looking structure. Previous studies ... contained increased levels of an asbestos-like mineral fiber that ...
    ... is full of examples of creatures that try to look ... potential predators. But to avoid being eaten alive the larvae ... a way exchanging a dollar for a couple of dimes. ... dollar larvae created clones of themselves within 24 hours of ...
    ... Genome Sequencing Center (GSC) at Washington University in St. Louis, ... the corn genome. In the fall of 2005 ... (USDA) and the Department of Energy (DOE), awarded $32 million ... of the project led by the Washington University GSC is ...
    Cached Biology News:Low exposure to asbestos-like mineral from Montana vermiculite may up lung disease risk 2Sand dollar larvae use cloning to 'make change,' confound predators 2Sand dollar larvae use cloning to 'make change,' confound predators 3All eyes and ears on the corn genome 2All eyes and ears on the corn genome 3
    ... immunological studies, vaccine development, and biosensor ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive Epitope Peptide Microarray ... Probe content is completely customer ...
    ... designed for quantitative assays using recombinant ... on the flexible and powerful Paraflo ... specified sequences can be synthesized on-chip ... with custom sequence design. These microarrays ...
    ... for the first time, you can identify ... more efficiently without interferences. The Agilent Multiple ... unwanted, multiple high-abundant proteins from human serum, ... just one device. With this revolutionary system, ...
    ... Microarrays designed for pathway studies, protein-protein ... (PTB) Studies built on the flexible ... platform. These microarrays are available as ... Microarray Service. Custom Probe ...
    Biology Products: